Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Radiation Therapy
100%
Proton Therapy
80%
Intensity Modulated Radiation Therapy
57%
Diseases
57%
Malignant Neoplasm
49%
Prostate Cancer
45%
Overall Survival
43%
Head and Neck Cancer
40%
Oropharynx Carcinoma
37%
Neck
36%
Re-Irradiation
32%
Breast Cancer
31%
Median Follow Up
26%
Clinical Trial
24%
Tonsil Cancer
23%
Breast Radiotherapy
23%
Immunotherapy
23%
Low Drug Dose
21%
Brachytherapy
21%
Progression Free Survival
20%
Systemic Therapy
19%
Chemotherapy
17%
Radiation Oncology
17%
Recurrent Disease
16%
Stereotactic Body Radiation Therapy
16%
Photon Therapy
16%
Cancer Therapy
16%
Neoplasm
15%
Oral
15%
Survival Rate
14%
Metastatic Carcinoma
13%
Relative Biologic Effectiveness
12%
Adverse Event
12%
Wart Virus
12%
Cosmesis
12%
Treatment Planning
12%
Arm
12%
Tongue
11%
Thoracic Wall
11%
Bladder
11%
Biochemical Recurrence Free Survival
10%
Drug Megadose
10%
Low-Dose-Rate Brachytherapy
10%
Biochemical Recurrence
10%
Cosmetics
10%
Kaplan Meier Method
10%
Contralateral
9%
Phase II Trials
9%
Brain Metastasis
9%
Cancer
9%
Keyphrases
Proton Therapy
57%
Head-and-neck Cancer
48%
Oropharyngeal Squamous Cell Carcinoma (OPSCC)
42%
Radiotherapy
39%
Radiation Therapy
35%
Re-irradiation
32%
Intensity-modulated Proton Therapy
32%
Overall Survival
28%
Single Institution
28%
Conventionally Fractionated
27%
Intensity-modulated Radiation Therapy
26%
Clinical Outcomes
25%
Head-and-neck
24%
Tonsil Cancer
23%
Hypofractionated Whole Breast Irradiation
23%
Partial Breast Irradiation
22%
Toxicity Outcomes
20%
Systemic Therapy
19%
Localized Prostate Cancer
18%
Phase II Trial
18%
Hypofractionation
18%
Intensity-modulated Radiotherapy
17%
Progression-free Survival
16%
Local Control
16%
Safety Outcomes
16%
Comprehensive Cancer Center
15%
Stereotactic Body Radiotherapy
15%
Radiation Oncology
15%
Intraoral Stent
15%
Early Outcomes
15%
Patients with Prostate Cancer
15%
Low-dose-rate Brachytherapy
15%
Brachytherapy Boost
15%
Low Dose Rate
15%
Liver
13%
Patient Outcomes
13%
Chemotherapy
13%
Late Toxicity
13%
Randomized Trial
12%
Proton
12%
Metastatic Disease
12%
Disease Control
12%
Prostate
11%
Intensity Modulation
11%
Tongue
11%
Breast Cancer Treatment
11%
Electronic Health Records
10%
Tertiary Cancer Center
10%
95% Confidence Interval
10%
Randomized Phase II Trial
10%